Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical announced that its subsidiary Chia Tai Tianqing has bought shares worth approximately HK$550 million under its Share Incentive Scheme, aimed at motivating and retaining employees. This move reflects the company’s confidence in its growth prospects and is part of a long-term strategy to enhance competitiveness and performance. The purchases, which took place between May and September 2024, will continue based on market conditions.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
